Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Deffered Revenue (2020 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $1.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2025, changed N/A year-over-year, with the annual reading at $5.2 million for FY2022, 83.38% down from the prior year.
  • Non-Current Deffered Revenue hit $1.7 million in Q3 2025 for IDEAYA Biosciences, down from $5.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $52.1 million in Q1 2021 to a low of $1.7 million in Q3 2025.
  • Historically, Non-Current Deffered Revenue has averaged $22.5 million across 3 years, with a median of $10.2 million in 2022.
  • Biggest five-year swings in Non-Current Deffered Revenue: dropped 15.02% in 2021 and later crashed 83.38% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $31.2 million in 2021, then plummeted by 83.38% to $5.2 million in 2022, then tumbled by 67.68% to $1.7 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for IDYA at $1.7 million in Q3 2025, $5.2 million in Q4 2022, and $7.3 million in Q3 2022.